p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance
about
Surmounting chemoresistance by targeting the Y-box binding protein-1Cancer Cell Fusion: Mechanisms Slowly UnravelFusion of CCL21 non-migratory active breast epithelial and breast cancer cells give rise to CCL21 migratory active tumor hybrid cell linesMelanoma chemotherapy leads to the selection of ABCB5-expressing cellsImpact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.Elevated expression of ABCB5 in ocular surface squamous neoplasia.Single-cell RNA-seq reveals activation of unique gene groups as a consequence of stem cell-parenchymal cell fusion.ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma.Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5Metabolic restriction of cancer cells in vitro causes karyotype contraction--an indicator of cancer promotion?An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.Fusion between M2-macrophages and cancer cells results in a subpopulation of radioresistant cells with enhanced DNA-repair capacity.Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1).Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors.LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population.ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells
P2860
Q27015900-241766CB-F051-4C5F-8441-CE3006A54C58Q28076643-D0BAF40B-A296-484E-9E9C-F32E87C8352FQ28487710-847C8F8A-804A-4B7C-A651-7ABA7BBD16B2Q34295399-821BADD0-2A06-46DA-B69C-DB4B26E1912AQ35558949-DD4D6430-97AC-4F1E-81FD-3C9E58C612A2Q35651467-9EE0C2EF-985A-4363-BB21-538414C6B164Q36542350-08674289-5893-4F5B-B05E-A76AECD05AF7Q36708133-D94E28EA-E2C7-4B05-9ECA-5BC94EB5B0A0Q36916308-3D771CE4-1C12-4C27-98EB-8AA3BED1893CQ37195479-4AADCC8C-21BA-499B-8BC2-3C73E19937C6Q37615286-A867C287-7485-49E8-A942-58EEFB664A32Q38026611-1C8C0A44-F52D-4835-A6CE-EF9E6E0E3045Q39441847-C8EEB722-8E84-4C29-8239-E1E571816C24Q39564235-2A61651A-A712-4A62-9E24-14069666C3CAQ41612788-624C90E2-EA1C-44B5-8C9D-F2A44667F78DQ41953034-8D386ACC-4585-4BE6-9ECE-739C3E9334BBQ43147021-6A84395D-D850-4646-9B46-7EFF72C7AFCDQ47222619-01972670-C46B-4F4E-9AFB-7350E75CEEB3Q51504173-DA8E0FCD-795C-4A2E-B3D2-99DB861C1A7FQ53476845-FD17B71C-6941-43B7-8313-7A711EDB633CQ53793272-517026FE-4C53-438C-A8D4-B4ED229C5037Q55421307-ACA69E3E-A30D-43DA-905D-D0A523FEDF8FQ55471424-F6C2D3DA-EAF2-4929-BCDB-830A22CA7745Q58765247-E55EBDFB-78E2-44A1-96E0-90D8BF46827E
P2860
p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@ast
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en-gb
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@nl
type
label
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@ast
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en-gb
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@nl
prefLabel
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@ast
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en-gb
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@nl
P2093
P2860
P3181
P356
P1433
P1476
p-Glycoprotein ABCB5 and YB-1 ...... ion and doxorubicin resistance
@en
P2093
Ji Yeon Yang
Jin Woo Kim
Seon-Ah Ha
Yun-Sik Yang
P2860
P2888
P3181
P356
10.1186/1471-2407-10-388
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1053361875